427 related articles for article (PubMed ID: 31135525)
1. T-Cell Receptor-Based Immunotherapy for Hematologic Malignancies.
Biernacki MA; Brault M; Bleakley M
Cancer J; 2019; 25(3):179-190. PubMed ID: 31135525
[TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
Boyiadzis MM; Dhodapkar MV; Brentjens RJ; Kochenderfer JN; Neelapu SS; Maus MV; Porter DL; Maloney DG; Grupp SA; Mackall CL; June CH; Bishop MR
J Immunother Cancer; 2018 Dec; 6(1):137. PubMed ID: 30514386
[TBL] [Abstract][Full Text] [Related]
3. T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance.
Chandran SS; Klebanoff CA
Immunol Rev; 2019 Jul; 290(1):127-147. PubMed ID: 31355495
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse.
Cummins KD; Gill S
Leuk Lymphoma; 2018 Jul; 59(7):1539-1553. PubMed ID: 28901790
[TBL] [Abstract][Full Text] [Related]
5. Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β.
Silk JD; Abbott RJM; Adams KJ; Bennett AD; Brett S; Cornforth TV; Crossland KL; Figueroa DJ; Jing J; O'Connor C; Pachnio A; Patasic L; Peredo CE; Quattrini A; Quinn LL; Rust AG; Saini M; Sanderson JP; Steiner D; Tavano B; Viswanathan P; Wiedermann GE; Wong R; Jakobsen BK; Britten CM; Gerry AB; Brewer JE
J Immunol; 2022 Jan; 208(1):169-180. PubMed ID: 34853077
[TBL] [Abstract][Full Text] [Related]
6. Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons.
Zhao Q; Jiang Y; Xiang S; Kaboli PJ; Shen J; Zhao Y; Wu X; Du F; Li M; Cho CH; Li J; Wen Q; Liu T; Yi T; Xiao Z
Front Immunol; 2021; 12():658753. PubMed ID: 33859650
[TBL] [Abstract][Full Text] [Related]
7. The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies.
Nagle SJ; Garfall AL; Stadtmauer EA
Cancer J; 2016; 22(1):27-33. PubMed ID: 26841014
[TBL] [Abstract][Full Text] [Related]
8. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.
Mercier-Letondal P; Marton C; Deschamps M; Ferrand C; Vauchy C; Chenut C; Baguet A; Adotévi O; Borg C; Galaine J; Godet Y
Hum Gene Ther; 2018 Oct; 29(10):1202-1212. PubMed ID: 30136612
[TBL] [Abstract][Full Text] [Related]
9. Adoptive T-cell therapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors.
Fujiwara H
Int J Hematol; 2014 Feb; 99(2):123-31. PubMed ID: 24352938
[TBL] [Abstract][Full Text] [Related]
10. T-Cell Receptor-Engineered Cells for the Treatment of Hematologic Malignancies.
Hossain NM; Chapuis AG; Walter RB
Curr Hematol Malig Rep; 2016 Aug; 11(4):311-7. PubMed ID: 27095318
[TBL] [Abstract][Full Text] [Related]
11. Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers.
Chen L; Qiao D; Wang J; Tian G; Wang M
Immunol Lett; 2019 Dec; 216():51-62. PubMed ID: 31597088
[TBL] [Abstract][Full Text] [Related]
12. TCR-Like CAR-T Cells Targeting MHC-Bound Minor Histocompatibility Antigens.
Akatsuka Y
Front Immunol; 2020; 11():257. PubMed ID: 32184779
[TBL] [Abstract][Full Text] [Related]
13. The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden.
Santomasso B; Bachier C; Westin J; Rezvani K; Shpall EJ
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():433-444. PubMed ID: 31099694
[TBL] [Abstract][Full Text] [Related]
14. Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer.
Anderson KG; Voillet V; Bates BM; Chiu EY; Burnett MG; Garcia NM; Oda SK; Morse CB; Stromnes IM; Drescher CW; Gottardo R; Greenberg PD
Cancer Immunol Res; 2019 Sep; 7(9):1412-1425. PubMed ID: 31337659
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of failure of chimeric antigen receptor T-cell therapy.
Li X; Chen W
Curr Opin Hematol; 2019 Nov; 26(6):427-433. PubMed ID: 31577606
[TBL] [Abstract][Full Text] [Related]
16. Escape From ALL-CARTaz: Leukemia Immunoediting in the Age of Chimeric Antigen Receptors.
Zheng S; Asnani M; Thomas-Tikhonenko A
Cancer J; 2019; 25(3):217-222. PubMed ID: 31135529
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma.
Stadtmauer EA; Faitg TH; Lowther DE; Badros AZ; Chagin K; Dengel K; Iyengar M; Melchiori L; Navenot JM; Norry E; Trivedi T; Wang R; Binder GK; Amado R; Rapoport AP
Blood Adv; 2019 Jul; 3(13):2022-2034. PubMed ID: 31289029
[TBL] [Abstract][Full Text] [Related]
18. An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines.
Ott PA; Dotti G; Yee C; Goff SL
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e70-e78. PubMed ID: 31099621
[TBL] [Abstract][Full Text] [Related]
19. Current landscape for chimeric antigen receptor T cells in lymphomas.
Skarbnik AP
Curr Opin Hematol; 2019 Nov; 26(6):421-426. PubMed ID: 31483334
[TBL] [Abstract][Full Text] [Related]
20. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma.
Ramachandran I; Lowther DE; Dryer-Minnerly R; Wang R; Fayngerts S; Nunez D; Betts G; Bath N; Tipping AJ; Melchiori L; Navenot JM; Glod J; Mackall CL; D'Angelo SP; Araujo DM; Chow WA; Demetri GD; Druta M; Van Tine BA; Grupp SA; Abdul Razak AR; Wilky B; Iyengar M; Trivedi T; Winkle EV; Chagin K; Amado R; Binder GK; Basu S
J Immunother Cancer; 2019 Oct; 7(1):276. PubMed ID: 31651363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]